Novel RET fusion RET-SEPTIN9 predicts response to selective RET inhibition with selpercatinib in malignant pheochromocytoma

摘要: Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma JCO Precis Oncol. 2021 Nov:5:1160-1165. doi: 10.1200/PO.21.00127. Authors Angela Mweempwa 1 , Huiling Xu 2 3 4 , Joseph HA Vissers 5 6 , Richard W Tothill 5 6 , Andrew D Pattison 5 , Andrew P Fellowes 2 3 , David M Thomas 7 , Gary Richardson 8 , Rodney J Hicks 6 9 , Sean M Grimmond 5 , Stephen B Fox 2 3 4 6 , Stephen J Luen 1 , Jayesh Desai 1 6 , Benjamin J Solomon 1 6 Affiliations 1 Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 2 Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 3 Cancer Research Division, Peter MacCallum Cancer Centre, …